GNT’s Multi-Target Stroke Drug Builds Hopes For Longer Window
This article was originally published in PharmAsia News
Executive Summary
GNT Pharma is set to begin a Phase II clinical trial of the world's first multi-target stroke therapy Neu2000, which may propose a new treatment method for ischemic stroke patients who receive revascularization treatment. The South Korean drug developer plans to seek a global licensing out deal for the drug, which is said to sharply extend the time window for stroke treatment, based on the outcome of the study.